News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Noble James
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/01/2022 |
4
| Noble James (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 710,711 options to buy
@ $0 |
|
| 07/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/07/2021 |
4
| Noble James (Director) has filed a Form 4 on GW PHARMACEUTICALS PLC|
Txns:
| Disposed/sold 27,492 shares
@ $0
Disposed/sold 18,636 options to buy
@ $9.8117, valued at
$182.9k
Disposed/sold 9,168 options to buy
@ $0.0017, valued at
$15.6
Disposed/sold 17,676 options to buy
@ $11.1742, valued at
$197.5k
Disposed/sold 10,740 options to buy
@ $0.0017, valued at
$18.3
Disposed/sold 16,548 options to buy
@ $14.3342, valued at
$237.2k
Disposed/sold 9,432 options to buy
@ $0.0017, valued at
$16
Disposed/sold 34,416 options to buy
@ $0.0017, valued at
$58.5
Disposed/sold 22,464 options to buy
@ $0.0017, valued at
$38.2 |
|
| 02/24/2021 |
4
| Noble James (Director) has filed a Form 4 on GW PHARMACEUTICALS PLC|
Txns:
| Granted 22,464 options to buy
@ $0 |
|
| 07/01/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/08/2020 |
4
| Noble James (Director) has filed a Form 4 on GW PHARMACEUTICALS PLC|
Txns:
| Granted 34,416 options to buy
@ $0 |
|
| 06/02/2020 |
4
| Noble James (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Sold 500,000 shares
@ $9.332, valued at
$4.7M
|
|
| 04/01/2020 |
4
| Noble James (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 31,000 options to buy
@ $0 |
|
| 01/15/2020 |
4
| Noble James (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Sold 100,000 shares
@ $4, valued at
$400k
Sold 200,000 shares
@ $5, valued at
$1M
|
|
| 05/29/2019 |
4
| Noble James (Director) has filed a Form 4 on GW PHARMACEUTICALS PLC|
Txns:
| Exercised 14,479 shares
@ $0.0013, valued at
$18.8
Exercised 68,117 shares
@ $4.8641, valued at
$331.3k
Sold 13,200 shares
@ $15.17, valued at
$200.2k
Sold 41,796 shares
@ $15.26, valued at
$637.8k
Sold 10,200 shares
@ $15.32, valued at
$156.3k
Sold 3,600 shares
@ $15.49, valued at
$55.8k
Sold 13,800 shares
@ $15.58, valued at
$215k
Exercised 14,479 options
@ $0
Exercised 34,061 options
@ $0
Exercised 34,056 options
@ $0 |
|
| 05/17/2019 |
4
| Noble James (CEO) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Exercised 1,773,100 shares
@ $0.143, valued at
$253.6k
|
|
| 03/05/2019 |
4
| Noble James (Director) has filed a Form 4 on GW PHARMACEUTICALS PLC|
Txns:
| Granted 16,548 options to buy
@ $0
Granted 3,144 options to buy
@ $0 |
|
| 01/08/2019 |
4
| Noble James (CEO) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 2,515,536 options to buy
@ $0
Granted 561,792 options to buy
@ $0 |
|
| 10/01/2018 |
3
| Noble James (Director) has filed a Form 3 on GW PHARMACEUTICALS PLC |
| 01/17/2018 |
4
| Noble James (CEO) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 1,719,936 options to buy
@ $0
Granted 384,120 options to buy
@ $0 |
|
| 01/18/2017 |
4
| Noble James (CEO) has filed a Form 4 on Adaptimmune Therapeutics PLC |
| 01/20/2016 |
4
| Noble James (CEO) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 1,968,016 options to buy
@ $0 |
|
| 01/06/2012 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 12/19/2011 |
3
| Noble James (Director) has filed a Form 3 on MELA SCIENCES, INC. /NY |
| 10/06/2009 |
4/A
| Form 4 - Statement of changes in beneficial ownership of securities [amend] |
| 10/05/2009 |
4
| Noble James (Director) has filed a Form 4 on CURAGEN CORP |
| 05/14/2009 |
4
| Noble James (Director) has filed a Form 4 on CURAGEN CORP |
|
|